Denis Chem Lab Peer Comparison

BSE: 537536

₹71.34

₹-1.44 (-1.98%)

As on 28-Aug-2026IST

Market cap

₹99 Cr

Revenue (TTM)

₹182 Cr

P/E Ratio

12.4

P/B Ratio

1.1

Div. Yield

3.5 %

Edit

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	99	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	182	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	7.98	735.15	678.07	666.92	169.62
Net Margin (%)	4.32	26.88	28.10	20.60	6.90
RoE (%)	8.90	19.16	19.73	18.75	20.76
Price to Earnings	12.41	29.25	28.74	28.35	104.74
Price-To-Book	1.06	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	181.72	2,519.65	1,937.47	2,893.64	2,275.58
Total Income	183.64	2,707.60	2,033.90	2,912.00	2,304.07
Total Expenditure	164.07	1,615.47	1,290.54	1,876.44	2,013.55
EBITDA	17.65	904.18	646.93	1,017.20	262.03
Depreciation	6.84	57.73	65.96	315.46	28.58
EBIT	10.81	846.45	580.97	701.74	233.45
Interest	0.84	9.57	0.61	231.29	4.49
Other Income	1.92	187.95	96.43	18.36	28.49
Exceptional Items	--	-49.16	--	--	-5.25
Profit before Tax	11.90	975.67	676.78	488.87	252.20
Provision for Tax	3.49	253.24	135.69	114.20	64.68
Profit after Tax	8.41	722.43	541.09	374.67	187.52

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	91.57	4,202.90	2,850.49	2,854.36	872.79
Minority Interest	--	--	35.90	417.40	--
Non-Current Liabilities	1.37	19.19	13.24	2,100.97	394.49
Current Liabilities	31.67	627.48	305.99	1,489.55	1,109.50
Total Liabilities	124.83	4,921.88	3,207.85	6,862.28	2,414.58

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	39.27	1,046.35	1,071.67	5,531.13	509.16
Current Assets	85.34	3,803.22	2,133.95	1,331.15	1,859.88
Total Assets	124.83	4,921.88	3,207.85	6,862.28	2,414.58
Total Debt*	4.18	2.50	0.55	2,421.66	0.00
Net Current Assets	53.68	3,175.74	1,827.96	-158.40	750.38
Contingent Liabilities	19.88	370.49	0.64	64.29	121.23

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	4.13	967.57	432.37	1,065.01	-15.14
Cash Flow from Investing Activities	-4.97	-561.67	-334.73	-79.97	18.69
Cash from Financing Activities	0.44	-798.31	-38.32	-881.32	-91.97
Net Cash Inflow / Outflow	-0.39	-392.41	59.32	103.72	-88.42

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	14.02	23.39	26.22	13.59	31.24
ROE (%)	9.52	17.16	21.72	13.81	23.02
ROA (%)	7.10	14.91	18.37	5.48	8.90
EBIT Margin (%)	10.77	43.34	38.37	35.79	12.77
Net Margin (%)	4.58	26.68	26.60	12.87	8.14
Cash Profit Margin (%)	8.39	29.72	31.33	23.22	9.47

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	4.86	10.45	14.37	44.02	32.59
EBIT Growth (%)	5.89	19.68	20.21	48.22	-1.38
Net Profit Growth (%)	4.13	-5.88	17.27	-5.65	62.02
EPS Growth (%)	4.13	-5.88	17.25	-10.39	62.02
Book Value Growth (%)	7.60	-0.34	23.77	10.19	13.51

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	9.33	29.89	28.38	54.83	103.45
Price / Book Value	0.86	5.14	5.52	6.78	22.39
Dividend Yield (%)	4.42	1.59	0.30	0.52	0.46
EV/EBITDA	2.74	16.93	19.78	20.75	65.23
Market Cap (₹ Cr)	78.47	21,592.90	15,219.80	19,292.77	19,398.64

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.05	0.00	0.00	0.85	0.00
Short term debt to equity ratio	0.04	0.00	0.00	0.14	--
Current Ratio	2.70	6.06	6.97	0.89	1.68
Quick Ratio	2.36	5.31	5.88	0.67	0.75
Interest Coverage	15.15	102.95	1,110.48	3.11	57.17

	Denis Chem Lab	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	21.27	7.22	32.65	15.85	9.39
Asset Turnover	1.53	0.54	0.66	0.43	1.08
Receivable days	69.56	26.06	110.70	54.07	31.88
Inventory Days	20.50	65.95	65.86	32.16	126.03
Payable days	80.18	81.01	105.88	140.91	163.79
Cash Conversion Cycle	9.88	11.00	70.68	-54.68	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.